How do you approach treatment selection between adjuvant pembrolizumab alone and pembrolizumab plus belzutifan in patients with clear cell renal cell carcinoma?

This is a very clinically relevant question given the recent approval of the combination. When facing a resected high-risk ccRCC patient, the first question is: what is the estimated risk of recurrence? Keep in mind that our current models are outdated, using features such as tumor size and grade, a...